283 related articles for article (PubMed ID: 12120185)
1. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
Baker DE
Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
[TBL] [Abstract][Full Text] [Related]
2. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
4. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
6. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
[TBL] [Abstract][Full Text] [Related]
8. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
9. Review article: tegaserod for chronic constipation.
Johanson JF
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.
Quigley EM; Wald A; Fidelholtz J; Boivin M; Pecher E; Earnest D
Clin Gastroenterol Hepatol; 2006 May; 4(5):605-13. PubMed ID: 16678076
[TBL] [Abstract][Full Text] [Related]
11. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
12. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
13. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
14. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
15. Tegaserod maleate (Zelnorm) for IBS with constipation.
Med Lett Drugs Ther; 2002 Sep; 44(1139):79-80. PubMed ID: 12237618
[No Abstract] [Full Text] [Related]
16. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
Wagstaff AJ; Frampton JE; Croom KF
Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
Al-Judaibi B; Chande N; Gregor J
Can J Clin Pharmacol; 2010; 17(1):e194-200. PubMed ID: 20410554
[TBL] [Abstract][Full Text] [Related]
20. Review article: tegaserod -- the global experience.
Chey WD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
